Understanding how tumors interact with the immune system in aggressive breast cancer
USING DEEP MUTATIONAL SCANNING TO CHARACTERIZE TUMOR-IMMUNE INTERACTIONS
This study is looking at how tumors and the immune system work together in people with triple negative breast cancer to find out which patients might respond best to a specific treatment called anti-PD-1 immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10818660 on NIH RePORTER |
What this research studies
This research investigates the interactions between tumors and the immune system specifically in patients with triple negative breast cancer (TNBC), a particularly aggressive form of the disease. By analyzing tumor samples from patients undergoing anti-PD-1 immunotherapy, the study aims to identify genetic changes and their impact on the tumor microenvironment. The researchers will use advanced imaging techniques and genetic sequencing to uncover patterns that may predict which patients are likely to benefit from immunotherapy. This comprehensive profiling could lead to the development of biomarkers that help tailor treatments to individual patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are considering or currently undergoing anti-PD-1 immunotherapy.
Not a fit: Patients with non-triple negative breast cancer or those not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify which TNBC patients are most likely to respond to immunotherapy, leading to more personalized and effective treatment options.
How similar studies have performed: Previous research has shown promise in using similar approaches to understand tumor-immune interactions, indicating potential for success in this area.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Greenwald, Noah — University of California, San Francisco
- Study coordinator: Greenwald, Noah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.